Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 9fludarabine phosphate 5fludarabine 5atezolizumab 4Paclitaxel 4Nivolumab 4Cyclophosphamide 4Cisplatin 4Cetuximab 4Carboplatin 4durvalumab 3Specimen Handling 3Pemetrexed 3Docetaxel 3Bevacizumab 3venetoclax 2ibrutinib 2encorafenib 2binimetinib 2Trastuzumab 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Practice Guidelines as Topic 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ipilimumab 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diagnostic Imaging × 30 days × Clear all
NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡